Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16

ConclusionUsing a machine learning approach, patients with moderate-to-severe AD and a BSA affecting 10 –40% and Itch NRS ≥ 7 were characterized as likely to benefit most from BARI 4-mg TCS combination therapy. This was confirmed by subgroup analyses, which showed that these patients are most likely to show favorable response rates in improving AD signs and symptoms, specifically itch, after 16  weeks of treatment.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research